Market Overview

JMP Securities Upgrades Myriad Genetics To Outperform


Analysts at JMP Securities upgraded Myriad Genetics Inc. (NASDAQ: MYGN) from Market Perform to Market Outperform.

The price target for Myriad Genetics is set to $50.

Myriad Genetics shares have surged 21.83% over the past 52 weeks, while the S&P 500 index has gained 15.35% in the same period.

Myriad Genetics' shares dipped 15.79% to $32.10 in pre-market trading.

Latest Ratings for MYGN

Jan 2019Cowen & Co.UpgradesMarket PerformOutperform
Jan 2019BarclaysMaintainsUnderweightUnderweight
Jan 2019NeedhamInitiates Coverage OnStrong Buy

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: JMP SecuritiesUpgrades Analyst Ratings


Related Articles (MYGN)

View Comments and Join the Discussion!

Latest Ratings

PEPMorgan StanleyReiterates137.0
AZRXH.C. WainwrightMaintains7.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Analysts: Suppliers May Gain From Automakers' Tech War

Compass Point Upgrades AthenaHealth To Outperform